A structure-conditioned workflow combining CycleRFdiffusion, ProteinMPNN and HighFold generated and screened 1,500 cyclic peptide–TREM2 complexes and prioritized four candidates. The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays. The authors report favorable plasma stability and moderate metabolic stability, presenting the work as an initial proof of concept for TREM2-targeted cyclic binders.
Technology: CycleRFdiffusion backbone design, ProteinMPNN sequence design and HighFold structural prediction/screening
Family RFdiffusion: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays.
- Still unknown: The only reported lead, TP4, is described as a weak binder. The evidence is biophysical binding and stability profiling, not demonstrated modulation of TREM2 signaling, microglial function, disease pathology or therapeutic efficacy. Treat this as proof-of-concept binder discovery.
- AI role: The AI pipeline generated and ranked 1,500 candidate cyclic peptide–TREM2 complexes based on structure, sequence and predicted energetics, from which four were selected for experiments; TP4 was then assessed with multiple orthogonal binding assays.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41435973/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A random-forest model integrating ATAC-seq, H3K27ac ChIP-seq and HiChIP data predicted enhancer effects across mouse trophoblast stem cells, embryonic stem cells and extraembryonic endoderm cells. CRISPRi tests supported a shared Enh14 hub regulating both Tfcp2l1 and Gli2 in embryonic stem cells, and an Enh4 hub linked to seven genes in extraembryonic endoderm; four of those seven showed expression reductions as predicted. Across 40 tested enhancer-promoter pairs, experiments yielded 12 true positives and 13 true negatives, with overall prediction accuracy 0.71.
Technology: 3D-HiChAT, an optimized Random Forest model combining chromatin accessibility, H3K27ac and 3D HiChIP connectivity features
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: CRISPRi tests supported a shared Enh14 hub regulating both Tfcp2l1 and Gli2 in embryonic stem cells, and an Enh4 hub linked to seven genes in extraembryonic endoderm; four of those seven showed expression reductions as predicted.
- Still unknown: The experiments were performed in mouse-derived cell lines, not intact embryos or human cells. Only selected predictions were tested; the 40-pair validation had 12 true positives, 13 true negatives and an overall reported accuracy of 0.71, leaving discordant/uncertain pairs. The Enh14 and Enh4 results support specific cell-type-dependent regulatory hubs but do not establish the full genome-wide predicted map as experimentally validated or prove developmental phenotypes in vivo.
- AI role: The model used 1D and 3D chromatin features to rank genome-wide enhancer-promoter pairs by predicted expression impact after in-silico enhancer perturbation. Researchers selected predictions for CRISPRi validation and measured target-gene expression by RT-qPCR; the paper reports specific validated multi-gene enhancer hubs and positive/negative prediction rates across 40 pairs.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10897904/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 51 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.